Pulsed Azithromycin for the Treatment of Dacomitinib Induced Skin Toxicity in Patient with Tetracycline Intolerance – A Case Report

Clicks: 6
ID: 323530
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #48 of 176 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Skin toxicities such as paronychia and acneiform rash are common side-effects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) and significantly altered the quality of life of patients. Consensus guidelines recommended tetracycline antibiotics as the first line choices for both prophylaxis and treatment for grade II-III acneiform rash and paronychia. While generally well-tolerated, a subset of patients experiences adverse effects such as nausea, vomiting, diarrhea, headache, and photosensitivity, leading to antibiotics intolerance and leaving EGFR TKI-induced skin toxicities unmanaged. Therefore, an alternative treatment is needed.Methods We present a case of stage IV EGFR-mutated non-small cell lung cancer (NSCLC) treated with the second-generation EGFR TKI, dacomitinib. The patient developed grade 3 skin toxicities and was subsequently treated with azithromycin after demonstrating intolerance to tetracycline antibiotics.Results Azithromycin was administered using various dosing strategies, and our findings indicated that 500 mg every other day might be the most effective regimen for treating EGFR-TKI-induced acneiform rash. However, this approach appeared to be less effective in managing paronychia.Conclusion This case highlights the potential efficacy of azithromycin 500mg once another day as an alternative to tetracycline antibiotics for managing EGFR TKI-related skin toxicities in NSCLC patients.
Reference Key
openalex_W4401884884 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wei Ho, Yi‐Ming Chen, Mong‐Wei Lin, Yu-Qing Liao, Chia‐Yu Chu, Shu‐Wen Lin
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag346
URL
https://doi.org/10.1093/ced/llag346
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.